Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06948214Phase 3Recruiting

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Role: lead

NCT05250063Phase 2Completed

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

Role: lead

NCT07129759Phase 3Not Yet Recruiting

Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency

Role: lead

NCT04614337Phase 2Completed

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

Role: lead

NCT05796440Phase 2Enrolling By Invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Role: lead

NCT04806854Phase 2Active Not Recruiting

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

Role: lead

NCT05469490Phase 1Withdrawn

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

Role: collaborator

All 7 trials loaded